Importantly, Jeong and co-workers have suggested that empagliflozin is able to improve respiratory function, reduce ischemia/reperfusion (I/R)-induced pulmonary edema and inflammatory cytokine production and protein concentration in the bronchoalveolar lavage (BAL) fluid through ERK1/2-mediated signalling pathway [37]. This evidence concerns the gene MAPK3 and edema.